JP2020529395A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529395A5
JP2020529395A5 JP2019569733A JP2019569733A JP2020529395A5 JP 2020529395 A5 JP2020529395 A5 JP 2020529395A5 JP 2019569733 A JP2019569733 A JP 2019569733A JP 2019569733 A JP2019569733 A JP 2019569733A JP 2020529395 A5 JP2020529395 A5 JP 2020529395A5
Authority
JP
Japan
Prior art keywords
cancer
zikv
composition according
mutation
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019569733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529395A (ja
JP7525853B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/036858 external-priority patent/WO2018231690A1/en
Publication of JP2020529395A publication Critical patent/JP2020529395A/ja
Publication of JP2020529395A5 publication Critical patent/JP2020529395A5/ja
Application granted granted Critical
Publication of JP7525853B2 publication Critical patent/JP7525853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019569733A 2017-06-12 2018-06-11 グリオブラストーマを治療するためのジカウイルス株 Active JP7525853B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762518300P 2017-06-12 2017-06-12
US62/518,300 2017-06-12
US201762574537P 2017-10-19 2017-10-19
US62/574,537 2017-10-19
PCT/US2018/036858 WO2018231690A1 (en) 2017-06-12 2018-06-11 Zika virus strains for treatment of glioblastoma

Publications (3)

Publication Number Publication Date
JP2020529395A JP2020529395A (ja) 2020-10-08
JP2020529395A5 true JP2020529395A5 (enExample) 2021-07-26
JP7525853B2 JP7525853B2 (ja) 2024-07-31

Family

ID=64660846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569733A Active JP7525853B2 (ja) 2017-06-12 2018-06-11 グリオブラストーマを治療するためのジカウイルス株

Country Status (6)

Country Link
US (1) US12274725B2 (enExample)
EP (1) EP3638304B1 (enExample)
JP (1) JP7525853B2 (enExample)
AU (1) AU2018283957B2 (enExample)
CA (1) CA3067164A1 (enExample)
WO (1) WO2018231690A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067164A1 (en) 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
US10993975B2 (en) 2017-08-07 2021-05-04 The Nemours Foundation Zika virus treatment of CD24-positive tumors and diseases associated with abnormal T cell activation and treating or preventing Zika virus infections
US12473570B2 (en) 2019-05-21 2025-11-18 The Regents Of The University Of California Zika virus constructs and therapeutic compositions thereof
CN113679744B (zh) * 2020-05-18 2023-12-29 中国人民解放军军事科学院军事医学研究院 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途
JP7846133B2 (ja) * 2021-05-04 2026-04-14 アリヴィッド エルエルシー 脳腫瘍治療のための生物学的実体物
CN119137275A (zh) * 2022-02-22 2024-12-13 维罗生物公司 溶瘤病毒和使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP1861491A4 (en) 2005-02-16 2009-07-08 Replikun Biotech Pty Ltd FLAVIVIRUS REPLICON CONSTRUCTS FOR ANTITUMOR THERAPY
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
WO2017004567A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
JP6896700B2 (ja) 2015-07-16 2021-06-30 バハラ バイオテック インターナショナル リミテッド ワクチン組成物
US20190202886A1 (en) * 2016-05-11 2019-07-04 Ohio State Innovation Foundation ONCOLYTIC VIRUSES COMPRISING esRAGE AND METHODS OF TREATING CANCER
US10786537B2 (en) 2016-08-18 2020-09-29 Cedars-Sinai Medical Center Method of inducing an oncolytic effect on tumor cells using Zika virus
CA3067164A1 (en) 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer

Similar Documents

Publication Publication Date Title
Rodrigues et al. Pathogenesis of cholangiocarcinoma
JP2019088286A5 (enExample)
JP2021104038A5 (enExample)
Welker et al. Recurrent hepatocellular carcinoma after liver transplantation–an emerging clinical challenge
Han et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma
CN103402545B (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
JP2010520758A5 (enExample)
BR112021013876A2 (pt) Codificação de rhabdovírus recombinante para ccl21
US20190144833A1 (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof
Osugi et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination
CA2517147A1 (en) Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
Hamid Epidemiology and outcomes of nasopharyngeal carcinoma
Khawkhiaw et al. Interleukin-1β: friend or foe for gastrointestinal cancers
BR112021004451A2 (pt) método para produção de um arenavírus antitumoral, bem como mutantes de arenavírus
Celik et al. A case with primary signet ring cell adenocarcinoma of the prostate and review of the literature
WO2022001080A1 (zh) 一种重组单纯疱疹病毒及其构建方法
WO2020238427A1 (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
JP2024508823A5 (enExample)
Qu et al. Up-regulation of long non-coding RNA MFI2 functions as an oncogenic role in cervical cancer progression.
Patalano et al. S3739 Acute Liver Failure Due to Metastatic Uveal Melanoma
JP2022539016A5 (enExample)
EP4556017A1 (en) Hepatitis b virus receptor oatp and use thereof
Shah The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma
Agüero et al. Neuroendocrine tumor and lutetium therapy
CN107970246B (zh) 非甾体类抗炎药在提高肿瘤细胞对酪氨酸激酶抑制剂的敏感性中的应用